Tags

Type your tag names separated by a space and hit enter

[Biosphonates in oncology].
Presse Med. 2000 Apr 08; 29(13):723-9.PM

Abstract

MECHANISM OF ACTION

Tumor-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Bisphosphonates inhibit bone resorption by reducing osteoclastic activity.

INDICATIONS

Bisphosphonates were shown to be effective in treating cancer-related hypercalcemia. Recent large randomized clinical trials have shown the efficacy of bisphosphonates in reducing bone pain, pathological fractures and spinal cord compression for patients with multiple myeloma and breast cancer metastatic to bone. The potential survival benefit from pamidronate in patients with advanced myeloma warrants further study.

FUTURE

Future clinical trials will use more potent bisphosphonates (zoledronate, ibandronate) with the ultimate goal of trying to prevent bone metastases.

Authors+Show Affiliations

Service de Rhumatologie, Hôpital de Bicêtre, Le Kremlin Bicêtre.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

fre

PubMed ID

10797827

Citation

Paule, B, et al. "[Biosphonates in Oncology]." Presse Medicale (Paris, France : 1983), vol. 29, no. 13, 2000, pp. 723-9.
Paule B, Clerc D, Brion N. [Biosphonates in oncology]. Presse Med. 2000;29(13):723-9.
Paule, B., Clerc, D., & Brion, N. (2000). [Biosphonates in oncology]. Presse Medicale (Paris, France : 1983), 29(13), 723-9.
Paule B, Clerc D, Brion N. [Biosphonates in Oncology]. Presse Med. 2000 Apr 8;29(13):723-9. PubMed PMID: 10797827.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Biosphonates in oncology]. AU - Paule,B, AU - Clerc,D, AU - Brion,N, PY - 2000/5/8/pubmed PY - 2000/6/8/medline PY - 2000/5/8/entrez SP - 723 EP - 9 JF - Presse medicale (Paris, France : 1983) JO - Presse Med VL - 29 IS - 13 N2 - MECHANISM OF ACTION: Tumor-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Bisphosphonates inhibit bone resorption by reducing osteoclastic activity. INDICATIONS: Bisphosphonates were shown to be effective in treating cancer-related hypercalcemia. Recent large randomized clinical trials have shown the efficacy of bisphosphonates in reducing bone pain, pathological fractures and spinal cord compression for patients with multiple myeloma and breast cancer metastatic to bone. The potential survival benefit from pamidronate in patients with advanced myeloma warrants further study. FUTURE: Future clinical trials will use more potent bisphosphonates (zoledronate, ibandronate) with the ultimate goal of trying to prevent bone metastases. SN - 0755-4982 UR - https://www.unboundmedicine.com/medline/citation/10797827/[Biosphonates_in_oncology]_ L2 - https://medlineplus.gov/fractures.html DB - PRIME DP - Unbound Medicine ER -